Date: 2015-09-15
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting, taking place on 14th – 18th September, 2015 in Stockholm, Sweden
Company: Zealand Pharma (Denmark)
Product: ZP-I-98
Action
mechanism: glucagon-like peptide-1 (GLP-1) receptor agonist/GLP-1 receptor agonist.
Disease: type 2 diabetes
Therapeutic area: Metabolic diseases
Country:
Trial details:
Latest
news: * On September 15, 2015, Zealand Pharma announced that new preclinical data on its novel GIP receptor agonist, ZP-I-98, will be presented at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting, taking place on 14th – 18th September, 2015 in Stockholm, Sweden. ZP-I-98 is invented and wholly-owned by Zealand. One investigational approach to enhance the efficacy of GLP-1 receptor agonists, used for the management of Type 2 diabetes, includes combination therapy with a glucose-dependent insulinotropic peptide (GIP) receptor agonist. Recent preclinical studies conducted by Zealand with its novel GIP receptor agonist, ZP-1-98, have shown that a GIP/GLP-1 combination therapy could enhance the treatment of Type 2 diabetes by inducing both robust glycemic control as well as a greater loss of body weight than seen by a single treatment. ZP-1-98 has a long-acting profile, which indicates that it could be suitable for convenient once-weekly dosing. “A novel GIP receptor agonist enhances the body weight lowering effect of Liraglutide in diet-induced obese mice and has the potential for once-weekly administration in humans” Presenter: Pia Noerregaard, Senior Scientist, Zealand
